Marcel Rozencweig
from Princeton, NJ
Marcel Rozencweig Phones & Addresses
- 92 Brookstone Dr, Princeton Township, NJ 08540 • (609)9212891 • (609)9212895 • (609)9213291
- 92 Brookstone Dr APT S2, Princeton, NJ 08540 • (609)9212895
- New York, NY
Resumes
Sevp Clinical Affairs At Sopherion Therapeutics
view sourcePosition:
SEVP Clinical Affairs at Sopherion Therapeutics
Location:
Greater New York City Area
Industry:
Biotechnology
Work:
Sopherion Therapeutics
SEVP Clinical Affairs
innate pharma 2009 - 2012
CMO
Medical Oncology Consulting 2001 - 2010
Consultant
SEVP Clinical Affairs
innate pharma 2009 - 2012
CMO
Medical Oncology Consulting 2001 - 2010
Consultant
Marcel Rozencweig
view sourceIsbn (Books And Publications)
Breast Cancer: Trends in Research and Treatment
view sourceAuthor
Marcel Rozencweig
ISBN #
0890040966
New Anticancer Drugs: Mitoxantrone and Bisantrene
view sourceAuthor
Marcel Rozencweig
ISBN #
0890048886
Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances
view sourceAuthor
Marcel Rozencweig
ISBN #
0898387272
Adriamycin: Its Expanding Role in Cancer Treatment Proceedings of the International Symposium on Adriamycin, July 14-16, 1983 Hakone, Japan
view sourceAuthor
Marcel Rozencweig
ISBN #
4900392227
Name / Title
Company / Classification
Phones & Addresses
Senior Evp, Clinical Affairs, Senior Executive Vice President
Sopherion Therapeutic Inc
Commercial Physical Research
Commercial Physical Research
104 Carnegie Ctr, Princeton, NJ 08540
PO Box 477, East Brunswick, NJ 08816
(609)9862021, (609)9862038
PO Box 477, East Brunswick, NJ 08816
(609)9862021, (609)9862038
Us Patents
-
Non-Pegylated Liposomal Doxorubicin Triple Combination Therapy
view source -
US Patent:8026267, Sep 27, 2011
-
Filed:Sep 10, 2010
-
Appl. No.:12/880037
-
Inventors:Marcel Rozencweig - Princeton NJ, US
Ronald H. Goldfarb - Guilford CT, US
Salvatore Forenza - Exton PA, US -
Assignee:Sopherion Therapeutics, LLC - East Brunswick NJ
-
International Classification:A61K 31/415
-
US Classification:514395
-
Abstract:The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.
-
Second Line Treatment Of Metastatic Hormone Refractory Prostate Cancer Using Satraplatin
view source -
US Patent:20090312295, Dec 17, 2009
-
Filed:Sep 24, 2007
-
Appl. No.:12/311032
-
Inventors:Thomas J. McKearn - New Hope PA, US
Marcel Rozencweig - Princeton NJ, US -
International Classification:A61K 31/282
A61K 31/573
A61K 31/439
A61P 35/00 -
US Classification:514171, 514492, 514299
-
Abstract:The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the 2line treatment of metastatic hormone refractory prostate cancer.
-
Treatment Of Pain Using Satraplatin
view source -
US Patent:20090325913, Dec 31, 2009
-
Filed:Sep 24, 2007
-
Appl. No.:12/311176
-
Inventors:Thomas J. McKearn - New Hope PA, US
Marcel Rozencweig - Princeton NJ, US -
International Classification:A61K 31/282
A61P 35/00
A61K 31/46
A61K 31/573 -
US Classification:514171, 514492, 514304
-
Abstract:The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the treatment of pain associated with metastatic hormone refractory prostate cancer.
-
Non-Pegylated Liposomal Doxorubicin Triple Combination Therapy
view source -
US Patent:20100260831, Oct 14, 2010
-
Filed:Apr 8, 2010
-
Appl. No.:12/756924
-
Inventors:Marcel Rozencweig - Princeton NJ, US
Ronald H. Goldfarb - Guilford CT, US
Salvatore Forenza - Exton PA, US -
International Classification:A61K 9/127
A61P 35/00
A61K 31/704
A61K 38/17
A61K 39/395
A61K 47/48 -
US Classification:424450, 514 34, 424 851, 4241331, 514 12
-
Abstract:The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.
-
Non-Pegylated Liposomal Doxorubicin Triple Combination Therapy
view source -
US Patent:20110256215, Oct 20, 2011
-
Filed:Jun 29, 2011
-
Appl. No.:13/172588
-
Inventors:Marcel Rozencweig - Princeton NJ, US
Ronald H. Goldfarb - Guilford CT, US
Salvatore Forenza - Exton PA, US -
Assignee:SOPHERION THERAPEUTICS LLC - East Brunswick NJ
-
International Classification:A61K 9/127
A61P 35/04
A61K 39/395 -
US Classification:424450, 4241331
-
Abstract:The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.
Marcel Rozencweig
view sourceFriends:
Anna Casazza, Noa Berman, Marcelle Ankaoua, Jim Alsup, Ravid Arbel
Youtube
Get Report for Marcel Rozencweig from Princeton, NJ